Cardioprotective effects of CYP-derived epoxymetabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activation
Darwesh et al. Can J Physiol Pahrmacol 2019
VISIT
Novel Roles of Epoxyeicosanoids in Regulating Cardiac Mitochondria
El-Sikhry et al. PLoS One 2016
VISIT
17,18-EEQ becomes the major upregulated EPA-metabolite when omega-3 fatty acid supplementation is given to man
Fischer et al. J Lipid Res 2014
VISIT
In transgenic mice overexpression of human epoxygenase CYP2J2 confers protection against ventricular tachycardia and atrial fibrillation
Westphal et al. PLoS One 2013
VISIT
CYP-eicosanoids – a new link between omega-3 fatty acids and cardiac disease?
Westphal et al. Prostaglandins Other Lipid Mediat. 2011
VISIT
Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids
Konkel and Schunck, Biochim Biophys Acta. 2011
VISIT
CYP enzymes efficiently convert EPA and DHA to novel bioactive lipid mediators that probably contribute to the cardiovascular beneficial effects of dietary omega-3 fatty acids. CYP2J2, the major CYP epoxygenase in the human heart prefers EPA as substrate and converts it to 17,18-EEQ
C Arnold et al. JBC 2010
VISIT
Relevance of soluble Epoxide Hydrolase (enzyme which is quickly de-activating 17,18-EEQ) in heart failure development – supporting evidence for relevance of CYP pathway as a therapeutic target in heart diseases
Monti et al. Nature Med 2008
VISIT
